Cargando…
Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
INTRODUCTION: The The BIOlogical Dose OPTimisation (BIODOPT) trial is a pragmatic, multicentre, randomised controlled, open-label, parallel-group, equivalence study designed to evaluate tapering of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA),...
Autores principales: | Uhrenholt, Line, Schlemmer, Annette, Hauge, Ellen-Margrethe, Christensen, Robin, Dreyer, Lene, Suarez-Almazor, Maria E, Kristensen, Salome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624054/ https://www.ncbi.nlm.nih.gov/pubmed/31292181 http://dx.doi.org/10.1136/bmjopen-2018-028517 |
Ejemplares similares
-
Association of biological antirheumatic therapy with risk for type 2 diabetes: a retrospective cohort study in incident rheumatoid arthritis
por: Paul, Sanjoy K, et al.
Publicado: (2021) -
Pseudoseptic Arthritis: An Initial Presentation of Underlying Psoriatic Arthritis
por: Paul, Prodip, et al.
Publicado: (2021) -
Comorbidities in Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2017) -
Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023) -
Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland
por: Burkard, Theresa, et al.
Publicado: (2022)